From a therapeutic perspective, the use of NAT2 genotyping may enhance the clinical benefits of amifampridine phosphate in patients with LEMS by minimizing the risk of AEs. The gene discussed is NAT2; the disease is Lambert-Eaton myasthenic syndrome.